Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person neratinib [cytosol]

Class:Id	ChemicalDrug:1216527
_displayName	neratinib [cytosol]
_timestamp	2020-12-11 15:23:40
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:1216529] Orlic-Milacic, Marija, 2011-02-15
crossReference	[DatabaseIdentifier:9628025] ChEBI:61390
disease	[Disease:1500689] cancer
modified	[InstanceEdit:1217500] Orlic-Milacic, Marija, 2011-02-17 [InstanceEdit:1220596] Orlic-Milacic, Marija, 2011-02-22 [InstanceEdit:1227678] Orlic-Milacic, Marija, 2011-03-09 [InstanceEdit:1227903] Orlic-Milacic, Marija, 2011-03-10 [InstanceEdit:1227909] Orlic-Milacic, Marija, 2011-03-11 [InstanceEdit:1667319] Orlic-Milacic, Marija, 2011-10-14 [InstanceEdit:9016686] Orlic-Milacic, Marija, 2017-08-14 [InstanceEdit:9028147] Weiser, JD [InstanceEdit:9616752] Shorser, Solomon, 2018-08-13 [InstanceEdit:9619952] Wu, G, 2018-09-19 [InstanceEdit:9627975] Wu, G, 2018-11-05 [InstanceEdit:9631716] Wu, G, 2018-12-12 [InstanceEdit:9646812] Orlic-Milacic, Marija, 2019-05-29 [InstanceEdit:9670632] Orlic-Milacic, Marija, 2019-12-11 [InstanceEdit:9709260] Jassal, Bijay, 2020-12-11
name	neratinib HKI-272 Irreversible tyrosine kinase inhibitor HKI-272 generic inhibits EGFR and ERBB2 (HER2)
referenceEntity	[ReferenceTherapeutic:9016681] neratinib [Guide to Pharmacology:5686]
stableIdentifier	[StableIdentifier:2018205] R-ALL-1216527.5
(activeUnit)	[NegativeRegulation:9649941] Negative regulation by 'Neratinib:ERBB2 KD mutant heterodimers [plasma membrane]'
(hasCandidate)	[CandidateSet:9655032] osimertinib,(afatinib,neratinib,sapitinib) [cytosol] [Homo sapiens]
(hasComponent)	[Complex:9649871] Neratinib:ERBB2 KD mutant heterodimers [plasma membrane] [Homo sapiens] [Complex:9665146] ERBB2 KD mutants:neratinib [plasma membrane] [Homo sapiens] [Complex:9665942] ERBB2 TMD/JMD mutants (neratinib):neratinib [plasma membrane] [Homo sapiens]
(hasMember)	[DefinedSet:1216531] Irreversible anti-EGFRplus TKIs [cytosol] [DefinedSet:1237431] afatinib, neratinib, lapatinib [cytosol] [Homo sapiens] [DefinedSet:9652360] lapatinib, neratinib, afatinib, AZ5104, tesevatinib, canertinib, sapitinib, CP-724714, AEE78 [cytosol] [CandidateSet:9654997] neratinib,osimertinib,tesevatinib,(afatinib,sapitinib) [cytosol] [CandidateSet:9655019] afatinib,neratinib,osimertinib,(lapatinib,sapitinib) [cytosol] [CandidateSet:9655113] neratinib,osimertinib,(sapitinib) [cytosol] [DefinedSet:9655128] afatinib,lapatinib,neratinib,osimertinib,sapitinib [cytosol] [DefinedSet:9655149] afatinib,neratinib,osimertinib,sapitinib [cytosol] [CandidateSet:9655178] afatinib,lapatinib,neratinib,osimertinib,(sapitinib) [cytosol] [CandidateSet:9655186] afatinib,neratinib,sapitinib,(osimertinib) [cytosol] [Homo sapiens] List all 18 refering instances
(input)	[FailedReaction:9665286] Resistant ERBB2 KD mutants do not bind neratinib [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9901076] Update Tracker - [ChemicalDrug:1216527] neratinib [cytosol] - v72:[removeName] [_UpdateTracker:9901981] Update Tracker - [ChemicalDrug:1216527] neratinib [cytosol] - v76:[modifyName]
[Change default viewing format]

No pathways have been reviewed or authored by neratinib [cytosol] (1216527)